DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Clinical trials for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted radiation attack on deadly brain tumors begins human testing
Disease control Recruiting nowThis early-stage study is testing whether a radioactive drug called Lutetium-177-PSMA-617 is safe for people with aggressive types of brain cancer called gliomas. The treatment uses a molecule that seeks out and delivers radiation directly to tumor cells that have a specific mark…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with devastating brain cancer: trial tests Life-Extending drug combos
Disease control Recruiting nowThis study is testing two different drug combinations to see if they can help children and young adults with aggressive brain tumors live longer. The trial is for patients who have just finished radiation therapy. One group receives two drugs (ribociclib and everolimus), while an…
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for brain cancer patients in groundbreaking UK drug trial
Disease control Recruiting nowThis UK trial is testing new oral drug combinations for aggressive brain tumors like glioblastoma. It aims to see if the drugs avutometinib and defactinib, given alone or with a standard chemotherapy, are safe and can help control tumor growth. The study will enroll 182 patients …
Matched conditions: DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC